GSK, previously operated as GlaxoSmithKline, on Monday completed the spinoff of its consumer product unit into a separate $36 billion business operating as Haleon.
The “de-merger,” which has been in the works for several years, means GSK (NYSE: GSK) will focus exclusively on vaccines and specialty medicines going forward.
The action is not expected to impact London-basked GSK’s Philadelphia operations in University City or Upper Providence, Montgomery County, where the Big Pharma company…
